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ABSTRACT 
 
Measuring HPV exposure relies on detection of HPV type-specific antibodies, but 
methods are not standardized.  Additionally, there is little information on the best sample 
type for HPV antibody detection.  This study validated pseudovirion neutralization 
(PVN) assay for HPV antibody detection and compared it to IgG ELISA.  Both assays 
were applied to paired serum and cervical mucus samples.  Additionally, PVN assay was 
utilized to evaluate the feasibility of oral mucosal transudate (OMT) samples to monitor 
the HPV immune response.  Serum was more likely to be positive on PVN assay than on 
IgG ELISA (p= 0.025). Both assays correlated with HPV-16 DNA status.  HPV-18 PVN 
assay results correlated with HPV-18 DNA status.  Few cervical mucus samples had 
detectable antibodies; no correlation with HPV DNA status was seen.  OMT results were 
unsatisfactory.   PVN assay was more sensitive than IgG ELISA; serum was a more 
reliable indicator of HPV-16/18 antibody status than cervical mucus.    
INDEX WORDS:  Human Papillomavirus, Antibody detection, IgG ELISA, 
Pseudovirion neutralization assay 
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Introduction 
Human papillomaviruses (HPV) are a significant public health problem.   HPV is 
the most common sexually transmitted infection in the United States. Each year there are 
an estimated 6.2 million new HPV infections in the United States alone.  It is estimated 
that 75% of sexually active women will be exposed to HPV in their lifetime. While the 
vast majority of infections are asymptotic and transient, persistent HPV infection is a 
significant risk for anogenital neoplasia.  In particular, HPV is detected in over 99% of all 
cervical cancers (Walboomers, Jacobs et al. 1999).  Worldwide, cervical cancer is 
associated with 300,000 deaths each year.  (Frazer, Cox et al. 2006; Lowy and Schiller 
2006; Trottier and Franco 2006; Markowitz, Dunne et al. 2007) 
 Papillomaviruses are a family of closely related double-stranded DNA viruses in 
the family Papillomaviridae.  Papillomaviruses have been found in nearly all animals, 
and maintain tight species specificity.  The viral particles are 55 nm in diameter, 
composed of a non-enveloped protein shell with a circular 8 kb genome (as reviewed in 
Zheng and Baker 2006).  The genome is similarly arranged in all papillomaviruses into 
three regions:  early, late, and non-coding regions.  The early region encompasses over 
50% of the genome and contains six or seven open reading frames (ORF) transcribed in a 
polycistron message from one DNA strand.  HPVs have six early ORFs coding for 
proteins E1, E2, E4, E5, E6, and E7 (as reviewed in Zheng and Baker 2006).  E1 and E2 
are involved in regulating viral DNA replication and transcription.  The E4 protein is 
produced during an active infection and is associated with cytokeratin filament collapse. 
Proteins E5, E6, and E7 are responsible for maintaining DNA synthesis in differentiated 
cells by inactivating the tumor cell repressors p53 and pRb.  This is required to allow the 
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virus to efficiently replicate and complete it life cycle.  However the action of these viral 
proteins also contributes to DNA instability and blocked apoptosis via the same 
pathways, so these proteins, particularly E6 and E7 also are the oncogenic proteins.  The 
late region consists of 40% of the papillomavirus genome, coding for the L1 and L2 
ORFs, which are the major and minor capsid proteins of the virus respectively (as 
reviewed in Zheng and Baker 2006).  The non-coding region encompasses the remaining 
10% of the papillomavirus genome.  This non-coding region contains numerous 
transcription factor binding sites that have been associated with the RNA polymerase II.  
(as reviewed in Zheng and Baker 2006) 
There are over 100 types of HPV; each designated a number based on the order of 
their discovery.  At least 40 HPV types can infect the genital area.  HPVs that affect the 
genital area can be divided further into subcategories of low and high risk.  Low risk 
types are those rarely associated with malignant lesions.  These types are associated with 
low grade squamous intraepithelial lesions (LSIL) of the cervix, genital warts and 
recurrent respiratory papillomatosis (wart-like growths in the upper respiratory tract).  
HPV 6 and 11 are responsible for the majority of the latter two lesions.  High risk types 
are those associated with malignancies, but these types are also most prevalent in the 
general population and are associated with LSIL as well as high grade squamous 
intraepithelial lesions (HSIL) of the cervix.  High risk HPV types include 16, 18, 31, 33, 
35, 39, 45, 51, 56, 58, 69, 73, and 82.  Worldwide, types HPV 16 and 18 are detected in 
70% of all cervical cancers.  High risk HPV has also been linked to other cancers such as 
vulvar, vaginal, penile, anal, and oropharyngeal cancer. (Frazer, Cox et al. 2006; Parkin 
and Bray 2006; Trottier and Franco 2006) 
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HPV is epithelioptropic, that is, infection is confined to epithelial cells. Based on 
papillomavirus model systems, infection is believed to be initiated in basal cells of the 
epithelium.  Basal cells may be accessible to infection as a result of minor epithelial 
trauma, or at squamocolumnar junctions, such as at the transformation zone of the cervix.  
The basal cells are undifferentiated self-renewing cells that have stem cell-like properties.  
In the basal layer of the epithelium the virus is maintained as an episome at relatively low 
copy numbers (10-50 copies per cell) (Stanley 2006).  
The virus is dependent on host cellular machinery for replication and 
transcription.  A differentiating environment is required for completion of the viral life 
cycle, and high copy number viral replication is noted in differentiating keratinocytes.  
This feature contributes to the inability to culture HPV in vitro.  As noted above, HPV E6 
and E7 prolong cellular replication in differentiated cells that would normally not be 
dividing.  This prolonged cell division results in a thickened epithelium, sometimes 
producing a wart-like growth.  The L1 and L2 genes are expressed in cells near the 
epithelial surface and complete viral particles self-assemble in the nucleus.  Virus is shed 
in association with cells as they exfoliate from the epithelium as part of terminal 
differentiation.  (Stanley 2006) 
The non-lytic nature of the infection and restriction of infection to the epithelial 
compartment results in minimal exposure of the virus to the host immune system.   
Nonetheless, both humoral and cellular immune responses can be detected.  Cellular 
immunity is most important for viral clearance, in particular macrophage and T cell 
response directed against the HPV E2 and E6 proteins (Stanley 2006).  While the innate 
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immunity initiates the first response to HPV infection, seroconversion, the production of 
antibodies, can take from 6 months to 1 year to occur (Carter, Koutsky et al. 2000).   
Additionally, it has been noted that the number of individuals that will never seroconvert, 
even though they are persistently HPV DNA positive, is less than 50 percent (Carter, 
Koutsky et al. 2000; Pagliusi, Dillner et al. 2006).  Thus, it is estimated that 70-80% of 
those exposed have detectable antibodies to HPV (Carter, Koutsky et al. 2000; Pagliusi, 
Dillner et al. 2006).  Once seroconversion has occurred, antibodies levels remain 
detectable for years (Scheurer, Tortolero-Luna et al. 2005).  Therefore seroprevalence is a 
relatively specific measure of viral exposure, but has limited sensitivity.   
Based upon inoculation studies, HPV seroconversion occurs via:  quick onset of 
IgM and IgA response, rapid decline in IgM with a slow descent of IgA antibodies, and 
finally the steady appearance of IgG antibodies (Scheurer, Tortolero-Luna et al. 2005).  A 
similar sequence of the IgA and IgG response is seen in cervical mucus; where presence 
of IgA is associated to current HPV infection and the presence of IgG was noted to be 
associated with lesion formation (Sasagawa, Rose et al. 2003; Bierl, Karem et al. 2005).  
Antibody production is important for protecting against the spread of infection and re-
infection.  (Lowy and Schiller 2006; Stanley 2006; Trottier and Franco 2006; Markowitz, 
Dunne et al. 2007)  
Despite the close similarity of all the HPVs, the antibody response is type-
specific.  A variety of experimental and in vitro systems have demonstrated that three 
dimensional conformational epitopes of papillomavirus virions are required to generate 
antibodies that block binding and infection. While antibodies can be detected against 
5 
 
linear peptide epitopes, only antibodies against conformational epitopes have neutralizing 
properties. (Carter, Wipf et al. 2003; Orozco, Carter et al. 2005)  
The L1 capsid protein, produced by recombinant protein expression systems, self 
assembles into structures that resemble intact virions when examined by electron 
microscopy.  Because of this resemblance, the empty protein shells are called virus-like 
particles (VLPs).  HPV type specific VLPs are used the target antigen in direct enzyme-
linked immunosorbent assays (ELISA).  In this format VLPs bound to ELISA plate are 
used as the target for binding of antibodies in the sample.  Antibodies to a specific 
immunoglobulin subclass are used to bind antibodies that recognize the VLPs.  The anti-
immunoglobulin antibody is either conjugated to an enzyme or hapten which is used to 
subsequently localize an enzyme.  The enzyme localization is revealed with a 
colorimetric or chemiluminescent substrate.  The indirect ELISA is a variation of this 
assay that uses an HPV type-specific antibody to bind the VLPs to the microtiter plate 
well.  The VLP ELISAs generally detect only one immunoglobulin subclass (e.g. IgG or 
IgA), dependent on the specificity of the detecting antibody. 
The VLP ELISA has been the gold standard for HPV antibody detection.  Yet, the 
VLP ELISA has several short comings.  VLPs can be produced in a variety of expression 
systems including insect cells, yeast and vaccinia.  Each method of production requires 
time consuming methods for purification of intact VLPs from the crude expression 
lysates.  Usually ultracentrifugation, electron microscopy and protein gel electrophoresis 
are required to evaluate the VLP preps.  While VLPs from each expression system would 
theoretically be equivalent reagents, they do differ in the type of non-specific antigen 
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carryover.  VLP preparations vary between laboratories and between lots within a 
laboratory.   
There are no commercial VLP reagents available, therefore each laboratory must 
undertake the production and quality control assays required for supplying the intact 
high-qualityVLPs that are central to the specificity of the ELISA.  In addition, methods 
for determining the cut-off for value a positive result are not standardized and positive 
and negative control samples are not available.  As a result the sensitivity and specificity 
of VLP ELISAs are difficult to validate.  In addition, unless a form dilution series is 
performed to determine the titer, the VLP ELISA does not offer a quantitative measure of 
antibodies.    
The competitive VLP ELISA is variation of the standard VLP ELISA assay 
(Wang, Christensen et al. 1997) in which the sample to be tested competes with an HPV 
type specific antibody for binding to the VLP.  A variety of detection methods are 
possible.  The competing antibody may be directly labeled with an enzyme, fluorescent 
tag or hapten, or, if produced in a different species such as mouse, detected with species-
specific labeled antibodies.  Samples that prevent the competing antibody from binding 
are considered true positives.  The type specificity of the assay is improved by the 
competing antibody.  However, particularly when monoclonal antibodies are used, some 
true positive samples may fail to compete because they recognize epitopes not 
represented in the competing antibody. 
Recently a  pseudovirion neutralization (PVN) assay was developed to evaluate 
serum antibodies (Buck, Pastrana et al. 2005).  Pseudovirions differ from VLPs in that 
they contain DNA.  In addition, like true virions, both L1 and L2 proteins are used to 
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make the pseudovirion.  While the minor capsid protein L2 does not significantly change 
the surface epitopes, L2 is required to increase the efficiency of capturing DNA.  The 
DNA in a pseudovirion is released when the particle binds to a cellular surface.  This 
mimics the infectious process and following the DNA from the pseudovirion allows an in 
vitro assessment of the first steps of the HPV infection.  The recently described assay 
uses secreted alkaline phosphatase (SEAP) as the reporter plasmid gene.  Release of 
alkaline phosphatase into the tissue culture media indicates “infection”.  Antibodies that 
bind to pseudovirions prevent the particles from binding to cells.  These neutralizing 
antibodies are type-specific and, in animal model systems, correlate with protection from 
infection.  Any immunoglobulin that binds to the pseudovirion is detected based on a 
reduction in the SEAP in the media.  Thus all neutralizing antibodies, regardless of 
immunoglobulin type are detected (e.g. IgG, IgA, etc.)    
There are numerous advantages to the PVN assay.  The pseudovirions are 
produced in cell lines transfected with expression plasmids for L1 and L2 proteins of 
HPV along with the SEAP plasmid.  Once the transfected cell lines are prepared, the 
production of pseudovirus is more efficient than VLP production.  Only type specific 
neutralizing antibodies will be detected and the detection of all immunoglobulins has the 
potential to improve sensitivity.  Additionally, ease of pseudovirion production facilitates 
assaying serum dilutions providing an antibody titer as a quantitative measure.  Initial 
studies indicate the PVN assay is more sensitive and specific than the ELISA (Pastrana, 
Buck et al. 2004). 
Theoretically, the PVN assay could be used with any sample that contains 
antibodies.  However to date it has only been applied to serum samples.  HPV ELISA 
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assays in cervical mucous are compromised by the lack of references for what would 
constitute a positive reaction as well as by low titers.  The PVN assay, by providing 
increased sensitivity and clear criteria for a positive result, could improve the analysis of 
the mucosal antibody response at the cervix.   
 Because the mucosal immune response is thought to be generalized, detection of 
antibodies at one mucosal surface (the cervix) should be linked to antibody detection at 
another mucosal surface (oral detection).  Oral antibodies can be collected using 
noninvasive sampling methods, and if correlated with serum and cervical response, 
would have advantages for monitoring populations for exposure to HPV.  Few studies 
have examined oral antibodies, and to date only VLP ELISAs have been used (Marais, 
Rose et al. 2000; Cameron, Snowhite et al. 2003).  While HPV antibodies were detected 
in oral fluids, this sample type was much less likely to be positive than the corresponding 
serum sample (Marais, Rose et al. 2000).   
The newly licensed vaccine against HPV has focused attention on potential 
clinical and public health applications of measuring antibodies to HPV.  In vaccine trials 
serum antibodies are used to monitor the response to vaccination.  Antibody titers seen 
after vaccination are much higher than those seen in natural HPV infection (Markowitz, 
Dunne et al. 2007).  Currently there is no antibody correlate of protection and HPV 
immunoassays are not recommended for individuals.  However antibody assays may play 
a role in post-vaccine surveillance in populations.  
The aims of this study were to establish and validate the PVN assay for HPV 16 
and 18 in serum, and to apply the assay to paired serum and cervical mucous collected in 
a in a subset of high risk adolescent females enrolled in a longitudinal study of HPV and 
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other sexually transmitted infections.  Results of the PVN assay will be compared to the 
direct VLP ELISA and known epidemiologic risk factors for HPV antibodies (such as 
HPV DNA detection and number of sex partners).  The assay will also be applied to oral 
fluid samples collected in the same study.  Results of this study will be used to determine 
the optimal sample type and testing method in future studies of HPV seroprevalence and 
post-vaccine surveillance studies.   
 Methods and Materials 
Study Population and Sample Collection 
The study population is a subset of those enrolled in a larger multi-objective 
longitudinal study of sexually transmitted infections conducted at a public pediatric clinic 
in Atlanta, Georgia (Koumans, Black et al. 2003).  Sexually active females age 13-19 
years were eligible to participate if a pelvic exam was indicated; participants were 
excluded if pregnant or HIV infected, or treated with antibiotics in the past month.  
Informed consent of the adolescent and consent of a parent/guardian or the consent of 
adolescents aged 18 or 19 years was obtained prior to enrollment.  At each visit a 
questionnaire was administered in private by trained interviewers (Tarkowski, Koumans 
et al. 2004).  The questionnaire included questions on demographics, sexual and 
reproductive history, condom use, drug, and alcohol use.  Visits were on average six 
months apart.  The study was reviewed and approved by the institutional review boards at 
the Centers for Disease Control and Prevention and Emory University. 
At each visit, biologic samples were collected including peripheral blood, 
exfoliated cervical cells, cervical mucus, and oral samples.  Oral samples were only 
collected as a pilot on a subset of participants.  The peripheral blood was collected via 
10 
 
venous puncture and allowed to clot at room temperature.  Serum was aliquotted and 
stored at -80 °C until use.   
At the time of pelvic examination, two weck-cel sponges (Medtronic, 
Minneapolis, MN) were placed into the cervical os until the sponges were saturated with 
cervical mucous (at least one minute).  The saturated sponges were placed into a labeled 
microfuge tube and placed on dry ice until transported to the laboratory for storage at -80 
°C until extraction.   
After collection of the cervical mucosal sample, endo- and exo-cervical samples 
were collected using the Cytyc plastic broom collection kit (Cytyc. Corporation, 
Boxborough, MA) and placed in 20 ml PreservCyt cytology fixative (Cytyc. Corporation) 
following manufacturer’s protocol for routine diagnostic ThinPrep Pap smear (Cytyc 
Corporation).  ThinPrep Pap smears were prepared and evaluated in the hospital 
cytopathology laboratory.  The cytologic diagnosis, based on Bethesda classification, was 
recorded from the resulting clinical report.  HPV detection and typing was performed on 
an aliquot of residual Thin Prep using L1 consensus PCR and the Roche Prototype line 
blot assay as previously described (Tarkowski et al. 2004).  The HPV DNA results were 
used to select subjects and samples for this study.   
Oral samples were collected using the OraSure collection device (OraSure 
Technologies, Bethlehem, PA).  The collection pad was rubbed across the gum line twice 
and then placed between along the lower gum line for 2 min.  The collection pad was 
then placed into a storage vial with storage buffer and centrifuged to collect the sample.  
Oral samples were stored at -20 °C until use, when they were thawed and heat inactivated 
at 56 °C in a water bath for 30 minutes. 
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Selection of Samples for Analysis 
  Detection of HPV 16 or 18 DNA in the cervical sample was used to indicate 
exposure.  For comparison of humoral and mucosal antibody detection, all women with a 
sample positive for HPV 16 or 18 were selected (exposure group) as were an equal 
number of women never testing positive for these types (comparison group).  The 
comparison group was matched to the exposure group based on age (± 6 months), race 
and number of sex partners.  Serum and mucosal samples collected from an individual 
within 180 days of each other were considered to be matched samples.  For the exposure 
group the samples had to be collected at or after the date of the positive PCR test.   
Of the 312 number of women enrolled in the original study, 64 were positive for 
16 or 18.  Of these, 36 had serum available (24 HPV 16 positive and 12 HPV 18 
positive).  All but one woman also had a matched mucosal sample.  Based on matching 
criteria, 35 women with a serum sample were available as the comparison group, 32 of 
whom had a matched mucosal sample.  The dates of sample collection fell between 
1/14/1999 and 12/12/05.     
For detection of oral antibodies, all 299 available samples collected from 209 
women were included.  These samples included 23 from women positive for HPV 16 and 
9 from women positive for HPV 18.  Only 16 women contributed samples to both the 
oral and humoral/mucosal study. 
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Cervical Mucus Extraction 
 Tubes containing the cervical mucus sample were removed from the freezer,  
placed on ice and incubated 30 minutes in 300 μl of lysis buffer (10 ml M-Per 
Mammalian Protein Extraction Reagent (Pierce, Pittsburgh, PA) to which 0.9 g NaCl 
(Fisher-Scientific, Pittsburgh, PA), and 1 tablet of Complete Mini, EDTA-free Protease 
Inhibitor Cocktail was added(Roche, Indianapolis, IN)).  The swab sticks were cut from 
the pad, and each pad was placed into a Spin-X centrifuge tube (Costar, Corning, NY) 
and centrifuged for 15 minutes at 16,000 X G.   An additional 300 μl of lysis buffer was 
added to the top of each Spin-X tube and the tubes were centrifuged as before.   The 
combined eluates from both spins were then aliquotted, 200 μl per tube, and stored at -
80° C until use. 
HPV 16 Virus Like Particle IgG Enzyme Linked Immunosorbent Assay (HPV 16 VLP IgG 
ELISA)  
 The HPV 16 VLP IgG ELISA was performed on both serum and mucosal 
samples as previously described (Karem, Poon et al. 2002).  Briefly, a 96-well microtiter 
plate (Fisher-Scientific, Pittsburgh, PA) was coated overnight at 4 ° C with HPV 16 
VLPs (0.1 μg/well; CDC in-house preparation).  The plate was washed and blocked at 
room temperature.  Serum and mucosal samples were diluted 1:20 and a 50 µl aliquot 
was added per well.  Duplicate wells on the same plate were used for each sample.  After 
a one hour incubation at 37° C, the plate was washed and detected 2 h at 37° C with a 
1:1000 dilution of Goat Anti-Human IgG-Alkaline Phosphatase conjugate (Roche).  
Following washing, signal was developed for 45 min. at room temperature with freshly 
prepared substrate (Sigma 104 Alkaline Phosphatase Substrate tablets, St. Louis, MO) 
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and read at 405 nm.  Each plate included eight control samples (four known positive and 
four known negative for HPV 16 based on blocking ELISA, described below).  A single 
lot of VLP was used for all assays in this study. The average value of the optical density 
(OD) for duplicate wells of each sample was calculated.  Serum samples with OD > 
0.275, a laboratory determined cut-off value based on results with inter-laboratory control 
sera were considered positive.  Mucosal results were handled as OD values because 
samples available for establishing a cut-off were not available.  
HPV 16 Blocking Assay   
 A blocking Assay was utilized to select HPV 16 positive and negative sera to be 
used as pooled and individual controls.  The IgG VLP ELISA was performed as 
described above with modifications as noted.  The microtiter plate was coated with 0.5 μg 
HPV 16 VLP  per well and blocking buffer was changed to 2% skim milk (Fisher-
Scientific) in 1 X phosphate buffered saline Tween 20 (PBST; Cellgro, Herndon, VA) 
and block performed  1.5 h at 37 ° C.  Sample diluent was changed (2% skim milk, 2% 
Goat Serum, 1% Insect Cell Lysate, 1 X PBST) and 50 µl volume per well was added.  
After 1.5 h incubation at 37 °C, 50 µl of mouse anti-HPV 16 monoclonal antibody (gift 
of Neil Christiansen, Hershey Medical Center) at two dilutions (1:100 and 1:200) were 
added to replicate wells and incubated an additional 1.5 h at 37 °C.  Conjugate was 
changed to goat anti-mouse IgG alkaline phosphatase (Chemicon, Temecula, CA) diluted 
at 1:1000 in 2% skim milk in 1 X PBST and incubation time was reduced to 1.5 hours.  
The ability of the sample to block the mouse monoclonal from binding to the VLP was 
calculated as [1- (OD value of Mouse Anti-16 with serum/OD value of Mouse Anti-16 
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alone)] x 100% for both the1:100 and 1:200 dilutions.  A value of ≥ 23% for either 
dilution was considered positive.   
HPV 16 VLP IgA Chemiluminescent Enzyme Linked Immunosorbent Assay (ELISA) 
 The IgA  chemiluminescent ELISA was performed as described in the IgG ELISA 
assay except the block consisted of 5% skim milk, 5% Goat Serum, 2% Bovine serum 
albumin, ((BSA) Sigma) in PBST.  OraSure samples were used undiluted.   A goat anti-
human IgA alkaline phosphatase conjugate (Calbiochem, San Diego, CA) was diluted at 
1:1250 in Conjugate Diluent (2% skim milk, 1% BSA, PBST).  BM Chemiluminescence 
ELISA Substrate (AP) (Roche) was prepared according to manufacturer’s protocol and 
50 µl was added to the plate.  The plate was incubated for 10 min. and was read on the 
Victor 2 Luminometer on the chemiluminescence setting. 
  Pseudovirion Neutralization (PVN) Assay                       
  The assay was performed according to Pastrana, Buck et al. (2004).  293TT 
human embryonic kidney cells (Invitrogen) were plated on 96-well tissue culture plates 
(Costar) at 30,000 cells/ well in neutralization buffer (Dulbecco’s Modified Eagle 
Medium (DMEM) without phenol red (Invitrogen), 10% heat-inactivated fetal bovine 
serum (FBS; Atlas Biologicals, Fort Collins, CO), 1% glutamax (Invitrogen), 1% 
nonessential amino acids (Invitrogen), 1% Hepes (pH 7.5) (Invitrogen), and 1% 
penicillin-streptomycin-fungizone (Invitrogen)).  Tissue culture plates were incubated for 
3 h at 37 ° C.   
Serum and mucosal samples were diluted 2-fold from 1:4 to1:512 in 
neutralization buffer.  22 μl of sample was added to 88 μl of HPV or BPV1 pseudovirions 
(PV; prepared as described below) on a 96-well microtiter plate (HPV 16 PV diluted at 
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1:200, HPV 18 PV diluted at 1:30, and BPV1 PV diluted at 1:250 in neutralization 
buffer).  The final sample dilutions ranged from 1:20 to 1:2560 for both serum and 
mucosal samples. Oral mucosal samples were diluted at 1:2, 1:4, and 1:8 in neutralization 
buffer and 22 μl of the sample was added to 88 μl of HPV 16 or BPV pseudovirion on a 
96-well microtiter plate ( PV diluted as describe above in neutralization buffer).  The 
final dilution of oral samples was 1:5, 1:10, and 1:20.   
HPV 16 pseudovirion plate positive controls consisted of pooled HPV 16 positive 
sera (in house samples verified on HPV 16 blocking assay) diluted at 1:180, and heparin 
(Sigma), diluted at 1 mg/ml.  The plate positive control for HPV 18 consisted of a mouse 
anti-18 monoclonal antibody, 5074 (Dr. John Schiller, NIH), and a mouse anti-16 
antibody (Dr. John Schiller, NIH) diluted at 1:20 was utilized as a negative control.  The 
plate positive control for BPV1 consisted of mouse anti-BPV 1 monoclonal 5B6 (Dr. 
John Schiller, NIH) diluted at 1:20,000.  Plate negative controls consisted of pooled HPV 
16 negative sera (in house samples) diluted at 1:540, neutralization buffer, and Anti-
papillomavirus  mouse monoclonal ( types 6, 11, and 18; Novocastra Laboratories Ltd, 
Tyne, United Kingdom) diluted at 1:100 for HPV 16, HPV 18 and BPV1 pseudovirion 
stocks.  2 2μl of each control was added to 88 μl of HPV or BPV1 pseudovirion and was 
added to the 96-well microtiter plate.  Samples and controls were incubated 1 h. with 
pseudovirions on ice, and 100 μl of each mixture was then added to the cells and cultured 
for 72 hours at 37 °C in a 5% CO2 tissue culture incubator.   
 A 50 μl aliquot of the cell supernatant was transferred into a 96-well round-
bottom microtiter plate (Costar) and incubated with 150 μl of Tris buffered saline (25mM 
Tris HCl, 150mM NaCl, pH 7.4; TBS) 30 min. at 65 °C.  After incubation, plates were 
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centrifuged for 5 min. at 3000 rpm and placed on ice for 5 min.  A 50 μl aliquot of the 
supernatant was transferred to a white chemiluminescent microtiter plate (Dynex, 
Chantilly, VA) and assayed for SEAP activity by adding 100 μl of BM 
Chemiluminescence ELISA Substrate (AP) (Roche, prepared as kit indicated), covering 
with an aluma-seal II plate cover (Excel Scientific, Wrightwood, CA) and incubating 
with shaking 10 min. at room temperature.  Plates were read on the Victor 2 
Luminometer set at glow-endpoint 0.20 sec/well.   
Preparation of L1, L2, and SEAP Plasmids for Pseudovirion Production 
 Recombinant plasmids (p16L1h, p16L2h, peL1fb, peL2bhb, pSheLL, pYSEAP; 
all received as a gift from John Schiller, NIH) were used to transform DH5-α competent 
E.coli cells (Invitrogen) as recommended by vendor.  Transformed clones were selected 
based on antibiotic resistance gene carried in the plasmid and used to prepare a 3 ml 
overnight culture.  Bacteria were lysed using detergent and boiling, and plasmid DNA 
extracted using the Qiagen HiSpeed Maxi Kit (Qiagen, Valencia, CA) according to the 
manufacturer’s protocol.  Plasmid DNA was resuspended in 1 ml of ddH2O and 
concentration was determined by absorbance at A260.   
To verify plasmid composition, PCR was performed.   
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Table 1.  Sense and anti-sense primers utilized for PCR according to the plasmid being 
amplified. 
Insert/ 
Plasmid 
Primer sequence (5’-3’) Primer 
length 
Tm 
(°C) 
Amplicon 
size (bp) 
16 L1 
p16L1h 
F-16L1/L2-920- AGGCCTGTACGGAAGTGTTAC 
R-16L1-2576 – ACAGATGGCTGGCAACTAGA 
F-16L1-1182- GGTGAGCGGCCTGCAGTACAG 
R-16L1-2353 – GTCCAGGTCGGCGCTGAA 
21 
20 
21 
18 
66.7 
67.0 
76.0 
74.5 
1675 
 
1189 
16 L2 
p16L2h 
F-16L1/L2-920 - same as above 
Reverse primer same as above (R-16L1-2576) 
F-16L2-1001-AGAGGAGCGCCAAGAGGACCAAG 
R-16L2-2385 – GCCAGGCTCACGTCGCTGAAG 
21 
20 
23 
21 
66.7 
67.0 
77.5 
78.0 
1580 
 
1404 
18 L1 
peL1fb 
F-18L1-785- CTAAAAGCTGCGGAATTGT 
R-18L1/L2 – TTCACTGCATTCTAGTTGTGG 
19 
21 
64.2 
64.9 
1611 
18 L2 
pL2bhb 
F-18L2-717 - CCTTGGAGCCTACCTAGACT 
R-18L1/L2 – same as above 
20 
21 
63.7 
64.9 
1579 
BPVL1 
pSheLL 
F-BPVL1-600- ACCGGACTCAGATCTCGAGAA 
R-BPVL1-2134- CGCGGTACCGTCGACTCTA 
21 
19 
69.8 
70.8 
1553 
BPVL2 
pSheLL 
F-BPVL2-2567 - CCTCAAGCGTATTCAACA 
R-BPVL2-4469 – TTTAATAGTGGACTCTTGTTC 
F-BPVL2-3181 -  GTCCATCGGCACAGACTCCTC 
18 
21 
21 
58.0 
57.3 
68.7 
1923 
SEAP 
pYSEAP 
F-SEAP-1683- GATCTGCGATCTAAGTAAGC 
R-SEAP-3391- TGTTAACTTGTTTATTGCAGC 
20 
21 
60.4 
61.8 
1729 
   
Amplicon size was verified by gel electrophoresis and restriction enzyme 
digestion.   5 μl of each amplicon, digested and undigested, was loaded into a 0.8% E-gel 
(Invitrogen) along with a DNA size standard. Gel was visualized under a UV light and 
compared to the DNA size standard.   
Pseudovirion production.  Pseudovirions were produced by transfecting 293FT 
(Invitrogen)  cells with plasmids coding for capsids (HPV 16 L1 and L2 for HPV 16, 
HPV 18 L1 and HPV 18 L2 for HPV 18, and BPV L1 for BPV1 respectively) as 
described by Buck, Pastrana et al. (2004).  Briefly, 293 FT cells were pre-plated in 
complete media without Geneticin (Invitrogen) or antibiotic-antimycotic in a 162 cm² 
flask (Corning) at 18 million cells per flask and incubated overnight at 37 °C with a 
humidified atmosphere of 5% CO2.  Cells were transfected with a total of 75 μg plasmid 
mix per T-162 cm² flask of 5% CO2 for 4-6 h at 37 °C in CO2 incubator.  [The plasmid 
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mix was composed of equal parts of each required plasmid (25 μg each if three plasmids; 
37.5 μg each if two plasmids) in Lipofectamine 2000 (Invitrogen).]  The media was then 
replaced with 30 ml of fresh complete media without antibiotics and cells were incubated 
overnight.  Cells were then split into a T-225 cm² flask (Corning) and cultured overnight 
in fresh media without antibiotics.  The media from the flask was then removed.  The 
cells were gently removed with trypsin and collected (Invitrogen).  The media/trypsin 
mix was centrifuged at 800 rpm for 7 min. at 4 °C.  All but 5 ml of the supernatant was 
discarded and the cells were resuspended in DPBS and centrifuged again as described 
above.  DPBS was discarded and the cell pellet resuspended in lysis buffer (DPBS 
supplemented with 9.5mM MgCl2, 0.025% Brij-58 (Sigma), 1% Benzonase (Sigma), and 
0.1% Plasmid Safe ATP Dependent DNase (Epicentre, Madison, WI)) at 100 million 
cells per ml.  The lysate was incubated at 37 °C for 24 h.  Beckman polyallomer tubes 
(Beckman Coulter, Fullerton, CA) were prepared with an Optiprep (Sigma) gradient and 
the gradient was allowed to diffuse for 1.5 h.  The cell lysate was chilled on ice for 10 
min.  A 0.17 volume of 5 M NaCl was added to chilled lysate and the mixture was iced 
for 10 min.  The lysate was centrifuged at 4600 rpm for 15 min. at 4 °C.  The supernatant 
was transferred to the top of the Optiprep tubes using siliconized tips (Bio Plastics INC) 
and centrifuged for 3.5 h. at 50,000 rpm.  Fractions were dripped into siliconized 
microcentrifuge tubes (Bio Plastics INC).  10 μl of each fraction was run on SDS-Page 
(BioRad, Hercules, CA) to determine which fraction contained pseudovirion.  Fractions 
containing pseudovirion were frozen at -80 °C until a titration assay was run on them to 
determine fraction concentration of pseudovirion. 
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Protein Assay  
 Total protein content of mucosal samples was determined using Coomassie Plus 
kit (Pierce) as per manufacturer’s protocol.  Bovine Serum Albumin Standard (BSA) 
(Pierce) was diluted in PBS to obtain the final concentrations of standard:  25, 20, 15, 10, 
5, and 2.5 μg/ml.  A blank was also run, containing only PBS.  Mucosal samples were 
thawed on ice and then diluted at 1:50 in PBS.  150 μl of each standard and each sample 
was placed on microtiter plate; all samples were run in duplicate.  150 μl of Coomassie 
Plus Protein Assay Reagent (Pierce) was added to each well and the plate was mixed by 
hand for 30 sec.  The microtiter plate was then incubated at room temperature for 10 min. 
and the absorbance was measured at 570 nm using the Victor 2 Luminometer.  A 
standard curve was plotted based on BSA standards in order to determine protein 
concentrations of each mucosal sample. 
Data Analysis 
 All data was analyzed utilizing Microsoft Office (Microsoft Corporation, Seattle, 
WA), SPSS 14.0 for Windows (SPSS INC, Chicago, IL), and SAS 9.1.3 for Window 
(SAS Institute INC, Cary, NC) software.  Standard curves, averages, standard deviations, 
absorbance, and chemiluminescence were determined using Microsoft Excel.  
McNemar’s Test determined the disparity between the discordant and the concordant 
PVN assay/ELISA results and was calculated using Microsoft Excel.  Fisher’s Exact Test 
determined the possible relationships between the PVN assay titers and HPV DNA status, 
the ELISA OD values and HPV DNA status, and the PVN titers and ELISA ODs; these 
were calculated via Simple Interactive Statistical Analysis website 
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(http://home.clara.net/sisa/).  Kappa Test (Landis and Koch 1977) showed the strength of 
correlation between PVN assay’s and ELISA assay’s HPV antibody detection.  Spearman 
correlation coefficient looked into the PVN assay titer and ELISA OD relationship as 
well as the serum and mucosal titer relationship.  Both Kappa Test and Spearman 
correlation were determined using SPSS.  Epidemiological data was analyzed in the form 
of odds ratios via SAS to determine if risk behaviors were associated with HPV infection. 
Results 
Study Population 
 The mean age of the 71 women in this study was 16.3 years (range, 13 -19 years); 
66 (93%) were African American.  They had been sexually active a median of 2 years 
(range 0 – 5 years) and had a median of 4 lifetime sex partners (range, 1-30 partners).  
Thirty three (47%) of the women had ever douched.  Smoking was common in this 
group; 23 (32%) smoked marijuana in the last 90 days, and 11 (15.5%) smoked tobacco 
in the last 90 days.  A summary of HPV DNA status for this group of women is in 
provided in Tables 1 and 1A. 
 Serum Samples 
HPV 16 antibodies.  The HPV 16 pseudovirion neutralization (PVN) assay detected the 
presence of HPV 16 antibodies in 41 of the serum samples (57.7%).  Positive titers 
ranged from 40 to 2560.  Seropositive women were significantly more likely to be HPV 
16 DNA positive than seronegative women (19/41, 46% versus 5/30, 16.7%; p = 0.006).   
  The HPV 16 IgG ELISA detected the presence HPV 16 antibodies in 15 of the 
serum sample (21.1%).  Seropositive women were significantly more likely to be HPV 16 
DNA positive than seronegative women (9/15, 60% versus 15/56, 26.8%; p = 0.015). 
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The results of HPV 16 antibody detection in serum by the PVN assay and the 
HPV 16 IgG ELISA (Table 2) showed a fair correlation (κ = 0.328).  The PVN assay was 
significantly more likely to be positive than the IgG ELISA (p = 0.025).  All IgG ELISA 
positive samples were also positive in the PVN neutralization assay.  The PVN 
neutralization titers also showed a significant correlation with the IgG ELISA optical 
density (OD) value (Figure 1; p = 0.01).  
The average PVN titer of concordant positive samples (PVN+/ELISA+) was 
significantly different from the discordant positive samples (PVN+/ELISA-); (1536 
versus 115; p = 0.001). While fewer women with concordant positive results were HPV 
16 DNA positive than those with discordant positive results (9/15, 60% versus 10/26, 
38.5%), the difference was not statistically significant.  However, women with a positive 
serum sample by either or both assays (concordant and discordant positive) were 
significantly more likely to be HPV 16 DNA positive than seronegative women (PVN-
/ELISA-) (5/30, 16.7%; p = 0.004 and 0.046 respectively).   
HPV 18 antibodies.  The HPV 18 PVN assay detected HPV 18 antibodies in 17 
(23.9%) samples.  Positive titers ranged from 40 to 2560.  Seropositive women were 
significantly more likely to be HPV 18 DNA positive than seronegative women (6/12, 
50% versus 11/59, 18.6%; p = 0.05).   
Cervical Mucus Samples 
The mean protein concentration of the mucosal samples was 803 ± 443 µg/ml 
(range 117-1847).  No attempt was made to control for this difference in protein 
concentration. 
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HPV 16 Antibodies.  The HPV 16 PVN assay detected HPV 16 antibodies in 6/67, 
(8.9%) mucous samples.  Positive titers ranged from 20 to 40.  Mucosal positive women 
were not more likely to be HPV 16 DNA positive than mucosal negative women (3/6, 
50% versus 20/61, 32.7%; p = 0.23).   
 The cut-off value for a positive result in the HPV IgG ELISA has not been 
established for mucosal samples.  However, the PVN titer showed a significant 
correlation with the IgG ELISA OD (Figure 2; p = 0.05).  But, the mean OD for the PVN 
positive samples was not significantly higher than the PVN negative samples (0.16 versus 
0.15). 
HPV 18 Antibodies.  The HPV 18 PVN assay detected HPV 18 antibody titers in 
2/67 (2.9%) samples.  Positive titers range from 20 to 160.  Mucosal positive women 
were not more likely to be HPV 18 DNA positive than mucosal negative women (1/2, 
50% versus 11/65, 16.9%; p = 0.13).    
Epidemiological Associations with Immune Assays 
 Risk factors significantly associated with HPV 16/18 infection based on the serum 
samples (Table 3 and Table 4) were lifetime number of 2-3 (p = 0.03) and ≥ 8 (p = 
0.03)sex partners, HPV 16 DNA status (p = 0.01), and HPV 18 DNA status (p = 0.03).  
No risk factors were significantly associated with HPV 16/18 infection based upon the 
cervical mucus samples (Table 5 and Table 6). 
Comparison of Serum and Mucosal Samples  
Paired serum and mucosal samples were available from 67 women, allowing 
direct comparison of humoral and local antibody response.   
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HPV 16 Antibodies.  While there was a correlation between HPV 16 PVN titers in 
serum and mucosal samples (Figure 3; p = 0.01), the positive results of each assay 
correlated poorly (Table 7, κ = 0.079).  Serum samples were significantly more likely to 
be positive than mucosal samples (p = 0.025, ± 5.02).  Women with HPV 16 PVN 
detectable antibodies in both serum and mucous samples were not more likely to be HPV 
16 DNA positive than those negative in both assays (2/5, 40% versus 4/27, 14%, p = 
0.19)  
HPV 18 Antibodies.   There was no correlation seen between the HPV 18 PVN 
titers in serum and mucosal samples (Figure 4).   The positive results of each assay 
correlated poorly (Table 8, κ = 0.055).  Serum samples were significantly more likely to 
be positive than mucosal samples (p = 0.025, ± 5.02).  Women with HPV 18 PVN 
detectable antibodies in both serum and mucous samples were not more likely to be HPV 
18 DNA positive than those negative in both assays (1/2, 50% versus 6/49, 12%, p = 
0.14)  
Oral Samples 
  The HPV 16 pseudovirion neutralization assay detected HPV 16 antibodies in 11 
(5.3%) samples from 209 women.  Of the 16 women with serum and/or mucosal samples, 
2 had a positive oral sample.  None of these women also had detectable antibodies in 
their serum or cervical mucous samples.  The OD of the HPV 16 IgA ELISA and PVN 
titers showed an inverse correlation (Figure 5; p = 0.01). 
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Table 2.  HPV DNA status for study population. 
 
HPV Status  
Exposure 
Group     
[N= 35] 
Comparison 
Group 
[N=36] 
Total 
Study 
Population 
[N=71] 
Negative (%) 0 (0) 19 (52.8) 19 
Single Type (%) 10 (28.6) 11 (30.5) 21 
Multiple Types (%)* 25 (71.4) 6 (16.7) 31 
*The number of types ranged from 2-7, mean = 3.2 
 
 
Table 2A.  HPV DNA status for study population.  
 
HPV Status  
Exposure 
Group     
[N= 35] 
Comparison 
Group 
[N=36] 
Total 
Study 
Population 
[N=71] 
Neg (%) 0 (0) 19 (52.8) 19 
High Risk (%) 35 (100) 12 (33.3) 47 
Low Risk Only (%) 0 (0) 5 (13.9) 5 
 
 
 
 
 
 
 
 
 
 
Table 3.  Comparison of HPV 16 antibody detection with the IgG ELISA and 
pseudovirion neutralization assay in serum.   
 
HPV 16 PVN Assay + PVN Assay - 
ELISA + 15 0 
ELISA  - 26 30 
 
 
 
 
 
25 
 
 
Table 4.  Univariate analysis of risk factors for detection of HPV 16/18 serum antibodies 
in a subset of high risk females (n = 70). 
 
Characteristic 
Total 
(n) 
PVN+ 16/18, no. 
(%) OR (95% CI) P 
Age         
≤15 7 0 (46.7) Reference   
16 22 12 (54.5) 1.37 (0.37 - 5.1)  0.63 
≥ 17 33 23 (69.7) 2.6 (0.75 - 9.2) 0.13 
Age of 1st Sex        
<14 21 13 (61.9) Reference   
14 19 11 (57.9) 1.08 (0.31 - 3.9) 0.89 
15 20 11 (55) 0.85 (0.25 - 2.8) 0.78 
≥16 10 7 (70) 1.6 (0.33 - 7.9) 0.55 
Lifetime Number of Sex 
Partners        
1 9 2 (22.2) Reference   
2-3 17 12 (70.6) 8.4 (1.3 - 55.4) 0.03 
4-7 30 18 (60) 5.3 (0.93 - 29.7) 0.06 
≥8 14 10 (71.4) 8.8 (1.2 - 61.7) 0.03 
Marijuana use in last 90 days        
Yes 23 12 (52.2) 0.62 (0.23 - 1.7) 0.35 
No 47 30 (63.8) Reference   
Smoking in last 90 days         
Yes 11 5 (45.5) 0.50 (0.14 - 1.8) 0.29 
No 59 37 (62.7) Reference   
Douching in last 90 days        
Yes 33 23(69.7) 2.3 (0.85 - 6.2) 0.10 
No 36 18 (50) Reference   
 
 
 
 
 
Table 5.  Univariate analysis of HPV 16 and HPV 18 DNA status for detection of HPV 
16 and 18 serum antibodies in a subset of high risk females (n = 71).  
 
Characteristic 
Total 
(n) PVN+ 16 no. (%) OR (95% CI) P 
DNA Status HPV 16 ONLY       
+ 24 19 (79.2) 4.3 (1.4 - 13.5) 0.01 
- 47 22 (46.8) Reference   
DNA Status HPV 18 ONLY   PVN+ 18 no. (%)    
+ 12 6 (50) 4.4 (1.2 - 16.1) 0.03 
- 59 11 (18.6) Reference   
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Table 6.  Univariate analysis of risk factors for detection of HPV 16/18 mucosal 
antibodies in a subset of high risk females (n = 66). 
 
Characteristic 
Total 
(n) 
PVN+ 16/18, no. 
(%) OR (95% CI) P 
Age         
≤15 4 1 (6.7) Reference   
16 19 2 (10.5) 1.6 (0.14 - 20.1) 0.69 
≥ 17 32 4 (12.5) 2.0 ( 0.20 - 19.6) 0.55 
Age of 1st Sex         
<14 21 1 (4.8) Reference   
14 18 2 (11.1) 0.75 (0.1 -5.9) 0.79 
15 19 1 (5.3) 1.8 (0.15 - 21.6) 0.64 
≥16 8 2 (25) 0.3 (0.04 - 2.6) 0.28 
Lifetime Number of Sex 
Partners         
1-3 22 2 (9.1) Reference   
4-7 28 3 (10.7) 1.2 (0.18 - 7.9) 0.84 
≥8 16 2 (12.5) 1.4 (0.18 - 11.4) 0.73 
Marijuana use in last 90 days         
Yes 19 2 (10.5) 0.98 (0.18 - 5.6) 0.98 
No 47 5 (10.6) Reference   
Smoking in last 90 days          
Yes 9 1 (11.1) 1.1 (0.11 - 10.0) 0.95 
No 57 6 (10.5) Reference   
Douching in last 90 days         
Yes 33 4 (12.1) 1.3 (0.27 - 6.5) 0.72 
No 32 3 (9.4) Reference   
 
 
 
 
 
Table 7.  Univariate analysis of HPV 16 and HPV 18 DNA status for detection of HPV 
16 and 18 mucosal antibodies in a subset of high risk females (n = 67). 
 
Characteristic 
Total 
(n) PVN+ 16, no. (%) OR (95% CI) P 
DNA Status HPV 16 ONLY         
+ 23 3 (13) 2.1 (0.38 - 11.1) 0.40 
- 44 3 (6.8) Reference   
DNA Status HPV 18 ONLY   PVN+ 18, no. (%)     
+ 12 1 (8.3) 4.9 (0.29 - 84.6) 0.27 
- 55 1 (1.8) Reference   
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Table 8.  Comparison of HPV 16 antibody detection in matched serum and mucosal 
samples run on HPV 16 pseudovirion neutralization assay. 
 
HPV 16 PVN Serum + PVN Serum - 
PVN Mucosal + 5 1 
PVN Mucosal  - 34 27 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 9.  Comparison of HPV 18 antibody detection in matched serum and mucosal 
samples run on HPV 18 pseudovirion neutralization assay. 
 
HPV 18 PVN Serum + PVN Serum - 
PVN Mucosal + 1 1 
PVN Mucosal  - 16 49 
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Figure 1. Comparison of ELISA OD value vs. pseudovirion neutralization assay 
titer of serum samples.   
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 Mucosal HPV 16 IgG ELISA vs. HPV 16 Pseudovirion Assay
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Figure 2.  Comparison of IgG ELISA OD vs. pseudovirion neutralization assay titer 
in mucosal samples.   
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Figure 3.  Comparison of mucosal titer and serum titer on HPV 16 pseudovirion 
neutralization assay. 
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Figure 4.  Comparison of mucosal titer and serum titer on HPV 18 pseudovirion 
neutralization assay. 
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Figure 5.  Comparison of HPV 16 IgA ELISA OD and HPV 16 pseudovirion 
neutralization assay titer in oral samples. 
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Discussion 
 This is one of the largest studies to compare the results of serum antibody 
detection using the PVN assay with the IgG VLP ELISA and the first to apply the same 
comparison to cervical mucosal samples.  This study design thus allows for the direct 
comparison of two assay platforms as well an investigation of both the local and humoral 
immune response.  In addition, both assays were applied to oral fluid samples to 
determine if this non-invasively collected sample would be an accurate reflection of 
serum antibodies, and thus suitable for population monitoring.   
While the serum PVN has been published, this assay requires considerable 
technical time and expertise to establish in a laboratory.  The CDC laboratory received 
the required constructs and training from Dr. Schiller’s laboratory and had established the 
assay for serum samples.  The first part of my thesis project was to establish and validate 
the assay in cervical mucous samples, an application not previously described.  The 
validity of the serum and mucosal PVN assays in my hands was established based on 
expected performance with QC samples, controls for non-specificity (BPV PVN controls) 
and results in dilution series. 
   In this study of 71 serum samples, detection of HPV 16 antibodies the HPV 16 
PVN assay was more sensitive and specific than the HPV 16 IgG VLP ELISA; as all 
ELISA positive samples were PVN positive and the ELISA assay failed to detect 
antibodies in 26 PVN positive samples.  This is in basic agreement with a previous study 
(Pastrana, Buck et al. 2004), although the absence of ELISA+/PVN- negative samples is 
somewhat unexpected.  Differences in the assay format account for some of the 
discrepancy.  The PVN assay is able to detect total immunoglobulin from both recent 
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(IgM, IgA) and past (IgG) HPV 16 infections, while the ELISA detects only IgG.  
Additionally, the ELISA assay may recognize non-neutralizing and cross-reactive 
antibodies not detected in the PVN assay.  As the samples tested are derived from a 
young population, there may be an unusually high number of recent exposures that 
explains the particular advantage of the PVN assay.   The validity of the PVN assay for 
HPV 16 and 18 is supported by the epidemiologic association with sexual exposure 
(lifetime numbers of sex partners) and HPV DNA status. 
Establishing the cut-off value is a particular vulnerability of the ELISA format.  In 
the absence of known controls, obtained primarily based on known epidemiologic status 
(such as samples from virgins with unlikely exposure to HPV, or HPV DNA positive) or 
verified by an independent assay, a cut-off value cannot be established.  This was the 
case for the HPV 16 ELISA in cervical mucous.  To compare HPV 16 antibody detection 
in cervical mucus via IgG VLP ELISA and the PVN assay, only the correlation of ELISA 
OD and PVN titer could be made.  While there was a significant correlation, few samples 
were positive in the PVN assay and there was no difference in the ELISA ODs of the 
positive and negative group.  Likewise there were few mucosal samples positive in the 
HPV 18 PVN assay.  As anticipated based on these limitations of the mucosal assays, the 
HPV 16 and 18 PVN assays in matched serum and mucosal samples were poorly 
correlated.  In addition, unlike results with the serum assays, the mucosal antibody assays 
did not correlate with HPV DNA status.  The relative lack of success with the mucosal 
samples may be due to using the same dilution as that used for the serum samples.  If 
titers are significantly lower in cervical mucous, the starting dilution may have prevented 
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accurate detection.  Future studies should examine less dilute mucous samples in order to 
provide more definite results.   
As expected, while there was a correlation between a woman’s HPV DNA status 
and serum PVN assay antibody results both in terms of titers and positive reactions, 
exceptions were noted.  It has been noted previously that antibodies to HPV 16/18 
infection can persist although the virus itself has been cleared (Pastrana, Buck et al. 2004; 
Einstein, Studentsov et al. 2007).  Thus, even though a woman may have tested HPV 
16/18 DNA negative, she may have been previously exposed to HPV and seroconverted.  
In addition, not all exposed women develop antibodies. 
Results of antibody testing in the oral samples were disappointing.  The PVN 
assay for HPV 16 was positive in only 5.3% of the oral samples.  This low detection of 
oral antibodies versus serum antibodies correlates with other studies (Marais, Rose et al. 
2000; Cameron, Snowhite et al. 2003).   However, the inverse correlation of HPV 16 
PVN titers with ELISA OD in these samples suggests the possibility of a non-specific 
substance reacting with the HPV 16 pseudovirus.  This was also the case with the oral 
HPV 18 PVN assay (data not shown); even after heat inactivation of the oral samples, the 
positive antibody reaction could not be diluted out.  This non-specific substance could be 
a component of the proprietary OraSure collection fluid, or occur as a result of 
deterioration due to long term freezer storage in this media.  The PVN assay may be 
successful if alternative collection methods, similar to those used in the studies cited 
above, were used.  In future studies a new set of oral samples should be collected and run 
on a competitive assay in addition to PVN assay.      
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This study demonstrates a favorable comparison between the results of the PVN 
assay and the VLP ELISA in both serum and mucosal samples.  This is in part due to 
ability to definitively establish a positive result based on neutralization.  The improved 
sensitivity of the PVN versus ELISA may not be generalizable to all populations, as the 
study focused on a unique population of young highly exposed women.  In this study 
serum was a more reliable indicator of HPV 16 and HPV 18 antibody status than cervical 
mucus or oral samples.  Improvements in assay conditions, specifically less dilute 
samples and alternative collection methods may improve results.  Because oral samples 
would represent a convenient sample for epidemiologic monitoring of HPV vaccine 
uptake in the population, this sample is worth further exploration.  As vaccination 
produces significantly higher titers than those that occur with natural exposure, the lower 
sensitivity of oral sampling may be overcome.   
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